Response to the KDOQI US Commentary on the 2018 KDIGO Hepatitis C Guideline.
(2021) American Journal of Kidney Diseases — Vol. 77, n° 1, p. 152 (2021)
Files
KamaretalResponsetotheKDOQIUSCommentary.pdf
Open Access - Adobe PDF
- 127.47 KB
Details
- Authors
- Abstract
- (en) TO THE EDITOR: In 2018, KDIGO issued a clinical practice guideline for the prevention, diagnosis, evaluation, and treatment of hepatitis C virus (HCV) infection in patients with chronic kidney disease. Recently, KDOQI published a commentary on the KDIGO guideline in which members of the appointed group disagreed with Recommendation 4.2.2 to direct HCV nucleic acid test (NAT)-positive kidneys to HCV NAT-positive recipients. They commented that recent studies demonstrated viral eradication with direct-acting antivirals (DAAs) in HCV NAT-negative patients who received HCV NAT-positive kidneys, thus providing evidence that such kidneys could be allocated to any recipients regardless of their HCV status. This is an important issue that deserves clarification.[…]
- Affiliations
Citations
Kamar, N., Morales, J. M., Gordon, C. E., Balk, E. M., Jadoul, M., & Martin, P. (2021). Response to the KDOQI US Commentary on the 2018 KDIGO Hepatitis C Guideline. American Journal of Kidney Diseases, 77(1), 152. https://doi.org/10.1053/j.ajkd.2020.07.014 (Original work published 2021)